DCGI approves trials for Biocon, Quark new eye drug
The Dollar Business Bureau India’s leading Biopharmaceutical firm Biocon Ltd on Thursday said that the Drug Controller General of India (DCGI) has given approval to it and its partner Israel-based Quark Pharmaceuticals Inc to go on with the clinical trials on human subjects for their new drug candidate, 'QPI-1007', which is aimed to treat ocular neuroprotection. Both the companies also informed the randomisation of first patient in the country in the Phase II/III global study of the latest drug candidate, Biocon said in a statement. Randomisation is referred to as providing subjects to treatment groups to check selection and accidental bias. “Biocon and Quark Pharmaceuticals have got the approval from DCGI to go on with the study, the first ever ...
Wipro wins five-year IT contract from Norwegian firm
The Dollar Business Bureau Indian IT major Wipro has won a five-year contract from Norwegian retailer giant Coop Norge Handel AS to upgrade the latter’s infrastructure and operating model. The IT engagement is expected to transform the supply chain and distribution operations, software landscape and data centric infrastructure of the Norwegian company, which has a market share of 33%, spread over 1,500 stores. “We believe the Wipro’s strong retails domain expertise, along with expertise in integrated infrastructure, will transform Coop Norge’s IT landscape, in line with the company’s business objectives,” said Srini Pallia, Chief Executive, Retail, Consumer Goods, and Transportation & Govt Business Unit, Wipro Limited. “This partnership reiterates our continued focus and investments in the Nordic region and Continental Europe,” ...
